Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 408

1.

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.

Nat Commun. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.

2.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Sep 4. doi: 10.1002/cncr.32445. [Epub ahead of print]

PMID:
31483485
3.

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.

Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, Gomella L, Kelly WK.

Eur Urol. 2019 Aug 2. pii: S0302-2838(19)30585-8. doi: 10.1016/j.eururo.2019.07.031. [Epub ahead of print]

PMID:
31420248
4.

Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.

Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, Ebot EM, Isikbay M, Finn SP, Giovannucci EL, Lis RT, Loda M, Parmigiani G, Lotan T, Kantoff PW, Mucci LA, Graff RE.

Int J Cancer. 2019 Jul 18. doi: 10.1002/ijc.32577. [Epub ahead of print]

PMID:
31318977
5.

Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.

Mazzu YZ, Yoshikawa Y, Nandakumar S, Chakraborty G, Armenia J, Jehane LE, Lee GM, Kantoff PW.

Mol Oncol. 2019 Sep;13(9):1944-1958. doi: 10.1002/1878-0261.12536. Epub 2019 Jul 19.

6.

Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6.

PMID:
31152158
7.

Aneuploidy drives lethal progression in prostate cancer.

Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. doi: 10.1073/pnas.1902645116. Epub 2019 May 13.

PMID:
31085648
8.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

9.

Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.

Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PW, Farokhzad OC, Zetter BR, Shi J.

Nat Biomed Eng. 2018 Dec;2(12):968. doi: 10.1038/s41551-018-0331-x.

PMID:
31015729
10.

Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.

Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PW, Farokhzad OC, Zetter BR, Shi J.

Nat Biomed Eng. 2018 Nov;2(11):850-864. doi: 10.1038/s41551-018-0284-0. Epub 2018 Sep 17. Erratum in: Nat Biomed Eng. 2018 Dec;2(12):968.

11.

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY.

Clin Cancer Res. 2019 Jul 15;25(14):4290-4299. doi: 10.1158/1078-0432.CCR-19-0404. Epub 2019 Apr 22.

PMID:
31010837
12.

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).

Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW.

Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.

PMID:
30996073
13.

Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer.

Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW.

Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1052-1058. doi: 10.1158/1055-9965.EPI-18-1083. Epub 2019 Mar 13.

PMID:
30867220
14.

Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

Van Rompay MI, Solomon KR, Nickel JC, Ranganathan G, Kantoff PW, McKinlay JB.

Eur J Cancer. 2019 May;112:118-126. doi: 10.1016/j.ejca.2018.11.033. Epub 2019 Mar 6.

PMID:
30850323
15.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
16.

Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.

Pike LRG, Wu J, Chen MH, Loffredo M, Renshaw AA, Pfail J, Kantoff PW, D'Amico AV.

Urology. 2019 Apr;126:145-151. doi: 10.1016/j.urology.2018.11.056. Epub 2019 Jan 18.

PMID:
30664895
17.

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):420-427. doi: 10.1038/s41391-018-0121-2. Epub 2019 Jan 14.

PMID:
30643173
18.

Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer.

Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):707-714. doi: 10.1158/1055-9965.EPI-18-1014. Epub 2019 Jan 2.

PMID:
30602500
19.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.

PMID:
30589920
20.

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME.

Cancer. 2019 Feb 15;125(4):524-532. doi: 10.1002/cncr.31836. Epub 2018 Nov 14.

PMID:
30427533
21.

Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.

Gagliano-Jucá T, Pencina KM, Ganz T, Travison TG, Kantoff PW, Nguyen PL, Taplin ME, Kibel AS, Li Z, Huang G, Edwards RR, Nemeth E, Basaria S.

Am J Physiol Endocrinol Metab. 2018 Dec 1;315(6):E1185-E1193. doi: 10.1152/ajpendo.00272.2018. Epub 2018 Oct 16.

PMID:
30325657
22.

Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.

Van Rompay MI, Curtis Nickel J, Ranganathan G, Kantoff PW, Solomon KR, Lund JL, McKinlay JB.

BJU Int. 2019 Mar;123(3):511-518. doi: 10.1111/bju.14534. Epub 2018 Oct 24.

PMID:
30216624
23.

Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.

Xie W, Stopsack KH, Drouin SJ, Fu H, Pomerantz MM, Mucci LA, Lee GM, Kantoff PW.

Prostate. 2019 Jan;79(1):73-80. doi: 10.1002/pros.23712. Epub 2018 Aug 23.

PMID:
30141208
24.

A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status.

Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, Lis RT, Graff RE, Pettersson A, Pernar CH, Loda M, Kantoff PW, Ahearn TU, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1231-1233. doi: 10.1158/1055-9965.EPI-18-0510. Epub 2018 Aug 14.

25.

Regular aspirin use and gene expression profiles in prostate cancer patients.

Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA.

Cancer Causes Control. 2018 Aug;29(8):775-784. doi: 10.1007/s10552-018-1049-5. Epub 2018 Jun 18.

26.

Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.

Mahal BA, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Natl Compr Canc Netw. 2018 Jun;16(6):727-734. doi: 10.6004/jnccn.2018.7010.

PMID:
29891524
27.

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C.

Prostate. 2018 Jun 7. doi: 10.1002/pros.23662. [Epub ahead of print]

PMID:
29882250
28.

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.

29.

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.

Gagliano-Jucá T, Travison TG, Kantoff PW, Nguyen PL, Taplin ME, Kibel AS, Huang G, Bearup R, Schram H, Manley R, Beleva YM, Edwards RR, Basaria S.

J Endocr Soc. 2018 Apr 20;2(5):485-496. doi: 10.1210/js.2018-00039. eCollection 2018 May 1.

30.

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.

31.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
32.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

33.

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. Erratum in: Nat Genet. 2019 Jul;51(7):1194.

34.

Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer.

Sun T, Du SY, Armenia J, Qu F, Fan J, Wang X, Fei T, Komura K, Liu SX, Lee GM, Kantoff PW.

Oncogenesis. 2018 Mar 13;7(3):30. doi: 10.1038/s41389-018-0039-5.

35.

Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.

McDuff SGR, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

Cancer. 2018 Apr 1;124(7):1391-1399. doi: 10.1002/cncr.31217. Epub 2018 Jan 16.

36.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

37.

Current treatment strategies for advanced prostate cancer.

Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW.

Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20. Review.

38.

Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.

Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV.

Cancer. 2018 Apr 1;124(7):1383-1390. doi: 10.1002/cncr.31204. Epub 2017 Dec 20.

39.

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20.

40.

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.

Hearn JWD, Xie W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M, Kantoff PW, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):558-562. doi: 10.1001/jamaoncol.2017.3164.

41.

Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.

Gagliano-Jucá T, Travison TG, Nguyen PL, Kantoff PW, Taplin ME, Kibel AS, Manley R, Hally K, Bearup R, Beleva YM, Huang G, Edwards RR, Basaria S.

J Pain Symptom Manage. 2018 Feb;55(2):307-317.e1. doi: 10.1016/j.jpainsymman.2017.09.017. Epub 2017 Sep 21.

42.

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.

Gui B, Hsieh CL, Kantoff PW, Kibel AS, Jia L.

PLoS One. 2017 Sep 8;12(9):e0184166. doi: 10.1371/journal.pone.0184166. eCollection 2017.

43.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. Erratum in: JAMA. 2018 Dec 11;320(22):2381.

44.

Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.

Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN.

Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2. doi: 10.1016/j.clgc.2017.07.014. [Epub ahead of print]

45.

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.

46.

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?

Mucci LA, Kantoff PW.

J Clin Oncol. 2017 Oct 10;35(29):3272-3274. doi: 10.1200/JCO.2017.74.7915. Epub 2017 Aug 17. No abstract available.

PMID:
28817369
47.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.

48.

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.

Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW.

Prostate. 2017 May;77(13):1303-1311. doi: 10.1002/pros.23390. Epub 2017 Aug 1.

49.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

50.

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.

Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML.

Cancer. 2017 Sep 15;123(18):3532-3539. doi: 10.1002/cncr.30808. Epub 2017 Jun 13.

Supplemental Content

Loading ...
Support Center